Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.61 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.59 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202509 | 1.00 | ALDH1A1 (0.61) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Formic Acid SCHEMBL30468942 | 0.93 | ALDH1A1 (0.53) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Nitric Acid SCHEMBL29118937 | 0.89 | ALDH1A1 (0.50) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL2000039 | 0.85 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL4186314 | 0.82 | GAA (0.59) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL27764010 | 0.82 | ALDH1A1 (0.59) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL28323645 | 0.80 | ALDH1A1 (0.57) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL9580010 | 0.80 | ALDH1A1 (0.57) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL10918990 | 0.79 | ALDH1A1 (0.55) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| SCHEMBL27714167 | 0.79 | F7 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| CN-118562565-A | Stable semiconductor chip cleaning liquid and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20240290431-A1 | BIOMARKER AND DIAGNOSIS SYSTEM FOR COLORECTAL CANCER DETECTION | HANGZHOU CALIBRA DIAGNOSTICS CO LTD (CN) | 2024-08-29 | — | — | US | claimed |
| CN-117554512-A | Simple beta-nicotinamide mononucleotide differential alpha-isomer and other related substance detection method | 江苏信佑生物有限公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117443319-A | Production process of 2-chloro-3-cyanopyridine | 老河口市天和科技有限公司 | 2024-01-26 | — | — | CN | claimed |
| WO-2023156070-A1 | COSMETIC COMPOSITION | THE BOOTS COMPANY PLC (GB) | 2023-08-24 | — | — | WO | claimed |
| WO-2023156069-A1 | COSMETIC COMPOSITION COMPRISING EXTRACT OF OPHIOPOGON JAPONICUS AND AT LEAST ONE CERAMIDE | THE BOOTS COMPANY PLC (GB) | 2023-08-24 | — | — | WO | claimed |
| WO-2023144235-A1 | METHODS FOR MONITORING AND TREATING WARBURG EFFECT IN PATIENTS WITH PI3K-RELATED DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-08-03 | — | — | WO | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-05-25 | — | — | US | claimed |
| US-6469035-B1 | REDUCING THE CAPACITY OF AN EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY ORALLY PRETREATING WITH AN AGENT WHICH INHIBITS OR REDUCES PROSTAGLANDIN PGD2 INDUCED BY NICOTINIC ACID; FDA ORANGE BOOK LISTED PATENT FOR NIACIN AND SIMVASTATIN | KOS LIFE SCIENCES LLC | 2002-10-22 | — | — | US | claimed |
| US-6143770-A | MIXTURES OF TOCOTRIENOL AND NICOTINIC ACID | LIPOGENICS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1017390-A2 | COMBINATIONS OF HMG-COA INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 2000-07-12 | — | — | EP | claimed |
| EP-0999844-A1 | PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO NICOTINIC ACID THERAPY | KOS PHARMACEUTICALS, INC. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006052-A9 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMA INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999006052-A1 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1999006035-A2 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| US-5472687-A | A water in oil or oil in water emulsion for treating hair loss ; free of hypotensive agent, side-effect reduction | PROCTOR PETER H (US) | 1995-12-05 | — | — | US | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| US-4568628-A | Water developable diazo printing plate composition with quaternary nitrogen stabilizer | POLYCHROME CORPORATION (US) | 1986-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157939-A1 | PERSONAL CARE COMPOSITIONS WITH ENHANCED SOLUBILITY ACTIVES | CUTA, CBS, SLC7A11 | ALDH1A1 3111/4885GAA 2143/4885APP 862/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | ALDH1A1 822/4885GAA 1419/4885APP 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.